Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HaemoVit is a hematinic combination product developed and manufactured by Boss Pharmacare, primarily used for the treatment and prevention of iron-deficiency anemia and as a general tonic for blood health. The formulation typically consists of ferrous fumarate, which provides elemental iron necessary for hemoglobin synthesis, along with a complex of B vitamins including thiamine (B1), riboflavin (B2), pyridoxine (B6), cyanocobalamin (B12), and nicotinamide. These vitamins act as essential co-factors in erythropoiesis (the production of red blood cells) and cellular energy metabolism. HaemoVit is widely marketed in Southeast Asia, particularly in Thailand, and is available in various formulations such as HaemoVit Gold, which may include additional multivitamins and minerals to support overall vitality.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HaemoVit.